An antiviral already on the market could be more effective than oseltamivir (Tamiflu) against avian influenza
A team in the US has tested the efficacy of baloxavir, an antiviral already on the market for treating common flu, against avian influenza in mice. The results, published in the journal Nature Microbiology, show that it is more effective than the currently recommended oseltamivir (Tamiflu) except when the infection is via the mouth, in which case it is equally effective. According to the authors, baloxavir ‘could be considered for the potential treatment of serious H5N1 virus infections in humans’.